Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG study

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5480-5487

  Tewari, Krishnansu S ^a   Sill, Michael W ^b   Monk, Bradley J ^c   Penson, Richard T ^d   Long, Harry J ^e   Poveda, Andrés ^f   Landrum, Lisa M ^g   Leitao, Mario M ^h   Brown, Jubilee ⁱ   Reid, Thomas J A ^j   Michael, Helen E ^k   Moore, David H ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CREIGHTON UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MAYO CLINIC   (United States)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g Oklahoma Health Science Center   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF CINCINNATI   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Franciscan St Francis Cancer Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AFRICAN AMERICAN; ARTICLE; BLACK PERSON; CANCER CHEMOTHERAPY; CANCER RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UTERINE CERVIX CANCER; VALIDATION STUDY; CANCER STAGING; CLINICAL TRIAL; KAPLAN MEIER METHOD; MORTALITY; ODDS RATIO; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CISPLATIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; ODDS RATIO; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84954088146     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1346     Document Type: Article

References (30)

1. Tewari KS, Monk BJ. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology. 8th ed. London, United Kingdom: Mosby; 2012, p. 51-119.
2. Monk BJ, Tewari KS, Koh WJ. Multi-modality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol 2007;25:2952-65.
3. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
4. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical carcinoma. Curr Oncol Rep 2005; 7:419-34.
5. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie 2009;32:552-4.
6. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: Commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.
7. Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004;92:635-8.
8. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2009;27:1069-74.
9. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.
10. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: Patient reported outcomes of a randomised, phase 3 trial (NRG Oncology - Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301-11.
11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer Version 1.2014 NCCN.org.
12. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010; 116:44-9.
13. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactor versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-71.
14. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-9.
15. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 2006;23:4626-33.
16. Bloss JD, Blessing JA, Behrens BC, Mannel Rs, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamidewith or without bleomycin in squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2002;20:1832-7.
17. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34: 187-220.
18. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: Trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170-80.
19. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol 2014;26:314-21.
20. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets formetastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.
21. Tewari KS. Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Expert Panel. Clin Ovarian Cancer 2011;4:90-3.
22. Moore DH. Chemotherapy for recurrent cervical carcinoma. Curr Opin Oncol 2006;18:516-59.
23. Somayaji D, Cloyes KG. Cancer fear and fatalism: How African-American participants construct the role of research subject in relation to clinical cancer research. Cancer Nurs 2014;38:133-44.
24. Haynes-Maslow L, Godley P, Dimartino L, White B, Odom J, Richmond A, et al. African-American women's perceptions of cancer clinical trials. Cancer Med 2014;3:1430-49.
25. Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol 2014;133:353-61.
26. Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG. Disparities in survival among women with invasive cervical cancer: A problem of access of care. Cancer 2009;115:166-78.
27. Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CE, et al. Somatic gene mutations in African-Americans may predict worse outcomes in colorectal cancer. Cancer Biomark 2013;13: 359-66.
28. Farley JH, Hines JF, Taylor RR, Carlson JW, Parker MF, Kost ER, et al. Equal care ensures equal survival for African-American women with cervical carcinoma. Cancer 2001;91:869-73.
29. Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of raceon tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: A pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199:539e1-6.
30. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48.